Application of Computational Biology and Artificial Intelligence in Drug Design

Abstract

Traditional drug design requires a great amount of research time and developmental expense. Booming computational approaches, including computational biology, computer-aided drug design, and artificial intelligence, have the potential to expedite the efficiency of drug discovery by minimizing the time and financial cost. In recent years, computational approaches are being widely used to improve the efficacy and effectiveness of drug discovery and pipeline, leading to the approval of plenty of new drugs for marketing. The present review emphasizes on the applications of these indispensable computational approaches in aiding target identification, lead discovery, and lead optimization. Some challenges of using these approaches for drug design are also discussed. Moreover, we propose a methodology for integrating various computational techniques into new drug discovery and design.

Artificial intelligence applications in disease diagnosis and treatment: recent progress and outlook

“…While this "AI model may not always outperform experienced clinicians," it "may potentially assist junior physicians in diagnoses". The study also discovered that the AI system could diagnose ailments with an accuracy of 90 to 95% (Zhang et al, 2022).…”

Viral proteases as therapeutic targets

“…Machine learning further boosts drug design. Here, an algorithm searches for general structural patterns of desired pharmacodynamical and/or pharmacokinetic properties in known molecules and tries to transfer these properties into structures of newly designed compounds ( Graff et al, 2021 ; Priya et al, 2022 ; Tanramluk et al, 2022 ; Zhang and Lee, 2019 ; Zhang et al, 2022 ). All the artificial intelligence (AI) approaches need experimental data sets for a starting input as well as for validation (e.g., X-ray structures, inhibition constants).…”

A comprehensive review of molecular optimization in artificial intelligence‐based drug discovery

“…In drug discovery, discovering novel drug candidates for preclinical trials can be summarized into five steps [4,5]. The first step is the identification of drug targets.…”

“…Annually, around 90% of drugs assessed by the Food and Drug Administration (FDA) are rejected and cannot be utilized for medicinal purposes [3]. Therefore, it is essential to consider efficient techniques to combat the rising cost and hasten the discovery process.In drug discovery, discovering novel drug candidates for preclinical trials can be summarized into five steps [4,5]. The first step is the identification of drug targets.…”